Opendata, web and dolomites


Clinical validation of Laser Optoacoustic Ultrasonic 3D Imaging System Assembly for breast cancer detection and characterization through endogenous biomarkers.

Total Cost €


EC-Contrib. €






 LOUISA-3D project word cloud

Explore the words cloud of the LOUISA-3D project. It provides you a very rough idea of what is the project "LOUISA-3D" about.

saturation    mammography    positive    combines    worldwide    treatment    predictive    modality    bcs    first    deaths    female    enter    digital    release    contrast    commercialized    hemoglobin    enhanced    board    introducing    complete    3d    validating    company    sensitivity    ionizing    capability    laser    market    standard    feasibility    exogenous    breast    screening    resonance    resolution    committee    media    validated    measuring    view    full    recall    effect    endogenous    nat    clinical    evaluation    once    population    opportunity    commercializes    diagnostic    assembly    representing    functional    financial    anatomical    therapy    scientific    plan    risk    detection    imaging    bios    trial    affordable    radiation    safe    tomography    business    device    locally    characterization    ultrasound    biomarkers    neoadjuvant    trials    limitations    marked    cancer    oxygen    manufactured    medical    coregistered    optoacoustic    magnetic    content    blood    ultrasonic    validate    commercialization    ce    protocols    women    bc    rate    images    louisa    overcome    international   

Project "LOUISA-3D" data sheet

The following table provides information about the project.


Organization address
address: VIA GUIDO ROSSA, 10/12
postcode: 20090
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOS S.R.L. IT (VIMODROME) coordinator 50˙000.00


 Project objective

Breast cancer (BC) is the most common cancer and the first cause of cancer-related deaths in European women. Laser Optoacoustic Ultrasonic 3D Imaging System Assembly (LOUISA-3D) combines optoacoustic functional information from endogenous biomarkers (hemoglobin content and blood oxygen saturation) with high-resolution anatomical images of ultrasound tomography, without the need for ionizing radiation or exogenous contrast media. The objective of LOUISA-3D is to overcome the main limitations of current imaging methods, by validating and introducing to the EU market a novel multi-modality diagnostic device for BC, based on coregistered full view 3D optoacoustic and ultrasonic technology. LOUISA-3D will be a highly effective, safe and affordable imaging method for BC detection, characterization, and evaluation of the effect of neoadjuvant therapy (NAT). Two clinical trials will validate LOUISA-3D. Trial 1 will measure detection rate, recall rate, sensitivity, and positive predictive value of LOUISA-3D as a screening test in a selected female population at increased risk for BC, as compared to standard digital mammography. Trial 2 will assess the LOUISA-3D endogenous biomarkers capability of measuring the NAT effect in the treatment of locally advanced BCs, as compared to contrast-enhanced magnetic resonance imaging. During this feasibility study, an international scientific committee will deliver both trial protocols, and a management board will release a work and financial plan for the trials and a business plan for the production and commercialization of LOUISA-3D, complete market analysis, cost analysis and financial plan. The applying company, Bios, commercializes medical laser systems worldwide. Once validated and CE medical marked, LOUISA-3D will be manufactured and commercialized in EU, representing an important opportunity for Bios to enter the medical imaging market and enable its significant growth.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LOUISA-3D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LOUISA-3D" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  


Integrating and decentralising diabetes and hypertension services in Africa

Read More